Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients

Results of a multicenter, prospective, longitudinal study

Authors

  • Kerstin Hermelink PhD,

    Corresponding author
    1. Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany
    • Frauenklinik der LMU Muenchen, Marchioninistrasse 15, D-81377 Muenchen, Germany===

    Search for more papers by this author
    • Fax: (011) 0049-89-70957582

  • Volkmar Henschel PhD,

    1. Institute of Medical Informatics and Biometry, Ludwig Maximilian University, Munich, Germany
    Search for more papers by this author
  • Michael Untch MD, PhD,

    1. Department of Gynecology and Obstetrics, Helios Clinic Berlin-Buch, Berlin, Germany
    Search for more papers by this author
    • Michael Untch has received honoraria from Pfizer, Novartis, and AstraZenaca.

  • Ingo Bauerfeind MD, PhD,

    1. Department of Gynecology and Obstetrics, Ludwig Maximilian University, Munich, Germany
    Search for more papers by this author
    • Ingo Bauerfeind has received honoraria from Novartis, AstraZeneca, and Pfizer.

  • Michael Patrick Lux MD, PhD,

    1. Department of Gynecology and Obstetrics, University of Erlangen, Erlangen, Germany
    Search for more papers by this author
    • Michael Patrick Lux has received honoraria for lectures from AstraZeneca, Novaris, and Pfizer and has received honoraria for consultancies from AstraZeneca, Novartis, and Pfizer.

  • Karin Munzel PhD

    1. Department of Psychology/Neuropsychology, Ludwig Maximilian University, Munich, Germany
    Search for more papers by this author

Abstract

BACKGROUND.

It is suspected that estrogen depletion resulting from treatment may contribute to cognitive compromise in patients with breast cancer. However, the evidence for estrogen effects on cognition is inconclusive, and the consequences of hormonal changes for cognitive function in patients with cancer rarely have been investigated. In this study, the authors investigated the effects of treatment-induced menopause and antiestrogen therapy with tamoxifen and aromatase inhibitors (AIs) on cognitive function.

METHODS.

Cognitive performance was assessed in 101 patients with breast cancer before the start of cancer therapy (T1), toward the end of neoadjuvant chemotherapy (T2), and 1 year after baseline (T3) using 12 cognitive tests. Menopause occurred in a subgroup of patients, and an overlapping subgroup started antiestrogen therapy with tamoxifen or AIs. Linear mixed-effects models that made it possible to determine effects at group levels and individual levels simultaneously were used for statistical analysis.

RESULTS.

At the group level, a significant favorable effect of induced menopause emerged in a test of executive function (P = .0035). Two additional group-level effects of induced menopause, both favorable, and 2 individual-level effects that were positive in some patients and negative in others were not significant when multiple testing was taken into account. No significant effects of tamoxifen or AIs on cognitive function were observed.

CONCLUSIONS.

Hormonal changes did not appear to contribute to cognitive compromise in patients with breast cancer during the first year after diagnosis. Antiestrogen treatment with tamoxifen or AIs did not affect cognition, and the effects of induced menopause were more likely to be favorable. However, the possibility that some cognitive decline occurs in individual patients could not be excluded. Cancer 2008. © 2008 American Cancer Society.

Ancillary